[Ip-health] KEI Research Note 2020:1 Role of the U.S. Federal Government in the Development of GS-5734/Remdesivir

Zain Rizvi zrizvi at citizen.org
Sat Mar 21 10:03:57 PDT 2020


This is great. Thanks for doing this.

The NIH has also disclosed that its phase 2 trial will cost at least $30 million this fiscal year.

https://twitter.com/joewalkerwsj/status/1233493135570980869?s=21

Zain

On Mar 21, 2020, at 12:53 PM, Claire Cassedy <claire.cassedy at keionline.org> wrote:

Kathryn Ardizzone has written a briefing note on U.S. federal support for
the development of GS-5734/Remdesivir.

https://www.keionline.org/RN-2020-1

KEI Research Note 2020:1 Role of the U.S. Federal Government in the Development
of GS-5734/Remdesivir

KEI Briefing Note 2020:1: Role of the U.S. Federal Government in the
Development of GS-5734/Remdesivir
Kathryn Ardizzone. March 20, 2020.

KEI-Briefing-Note-2020_1GS-5734-Remdesivir:
https://www.keionline.org/wp-content/uploads/KEI-Briefing-Note-2020_1GS-5734-Remdesivir.pdf
_______________________________________________
Ip-health mailing list
Ip-health at lists.keionline.org
http://lists.keionline.org/mailman/listinfo/ip-health_lists.keionline.org


More information about the Ip-health mailing list